Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Heartland Value Plus Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-conviction value plays like WCC and LAMR as small-cap earnings growth is poised to outpace large caps."
During Q4 2025, the Heartland Value Plus Fund observed a broadening of the market as small-cap value stocks outpaced the majority of the Magnificent 7. Although the Value Plus Strategy was down 0.10% (underperforming the 3.26% gain of the Russell 2000 Value Index due to zero exposure to non-earning biotech companies in Health Care), the managers remain highly constructive on the small-cap landscape. Key holdings Lamar Advertising (LAMR) and Builders FirstSource (BLDR) showcase strong fundamental backings like share buybacks and insider buying. A new position was initiated in WESCO International (WCC), which possesses attractive automation-driven margin expansion and double-digit EPS growth potential.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Growth Outlook
Market outlook remains above average conviction: The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Risk Appetite
Risk appetite posture is above average conviction: The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Forward Guidance
Forward guidance signal: The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Language Signal
Tone analysis indicates above average conviction language: The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
Time Horizon
Investment time horizon reflects a high conviction orientation. The Heartland Value Plus Fund slightly underperformed in Q4 2025 due to avoiding unprofitable biotech companies, but remains highly optimistic for 2026, positioning into high-convi...
